Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10909)
  2. Meeting Abstract (9499)
  3. Review (552)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (157)
  7. Correspondence (117)
  8. Conference Paper (106)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22212)
  2. GSK Faculty (5923)
  3. Genitourinary Oncology Service (5644)
  4. Survivorship Research (5222)
  5. Gastrointestinal Oncology Service (4681)
  6. Breast Medicine Service (4153)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (791)

More People

Years
  1. 2025 (612)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5282)
  2. Annals of Oncology (1296)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (531)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5574)
  2. Elsevier Inc. (2659)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1818)
  5. Nature Publishing Group (1039)
  6. Springer (980)

More Publishers

Results (22235)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
    Meeting Abstract

    Venugopal, B.; Choueiri, T. K.; Penkov, K. D.; Albiges, L.; Uemura, H.; Larkin, J.; Tomita, Y.; Wang, J.; Hoffman, J.; Gerhold-Ay, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
    Meeting Abstract

    Kyriakopoulos, C.; Chatta, G.; Laccetti, A. L.; Iannotti, N.; Sokolova, A. O.; Hotte, S. J.; Tutrone, R.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Appleman, L. J.; Taplin, M. E.; Juárez, Á.; Zhang, L.; Chen, Y.; Gupta, N.; Saltzstein, D.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
    Meeting Abstract

    Hofman, M. S.; Gafita, A.; Bressel, M.; Alipour, R.; Levy, S.; Emmett, L.; Ravi Kumar, A. S.; Hamid, A. A.; Buteau, J. P.; Kuo, P. H.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
    Meeting Abstract

    Armstrong, A. J.; Appleman, L. J.; Danila, D. C.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P. J.; Pook, D. W.; Kim, M.; Dorff, T. B.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
    Meeting Abstract

    Chi, K. N.; Sartor, O.; Fizazi, K.; de Bono, J. S.; Shore, N. D.; Herrmann, K.; Castellano Gauna, D. E.; Piulats Rodriguez, J. M.; Flechon, A.; Wei, X. X.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Nakajima, T.; Moran, D.; Yang, J.; Li, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save